Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic.

MLA

Akimova, A. A., et al. “Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic.” Doklady. Biochemistry and Biophysics, vol. 518, no. 1, Oct. 2024, pp. 291–99. EBSCOhost, https://doi.org/10.1134/S1607672924701060.

APA

Akimova, A. A., Banshchikova, N. E., Sizikov, A. E., Mullagaliev, A. A., Letyagina, E. A., Ilina, N. A., Kurochkina, Y. D., Ubshaeva, Y. B., Omelchenko, V. O., Chumasova, O. A., Shkaruba, N. S., & Korolev, M. A. (2024). Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic. Doklady. Biochemistry and Biophysics, 518(1), 291–299. https://doi.org/10.1134/S1607672924701060

Chicago

Akimova, A A, N E Banshchikova, A E Sizikov, A A Mullagaliev, E A Letyagina, N A Ilina, Y D Kurochkina, et al. 2024. “Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic.” Doklady. Biochemistry and Biophysics 518 (1): 291–99. doi:10.1134/S1607672924701060.